A
Amgen
Develops human therapeutics for various diseases
About Amgen
Amgen is a leading biotechnology company focused on developing innovative medicines to serve patients and address serious illnesses. Operating in the healthcare and pharmaceutical markets, Amgen's core business involves the research, development, and commercialization of therapeutic solutions. The company primarily serves patients with serious diseases, healthcare providers, and medical institutions globally. Amgen's business model is centered around the discovery and development of biologic therapies, which are medicines derived from living organisms. These therapies are designed to treat conditions such as cancer, cardiovascular disease, and autoimmune disorders. The company generates revenue through the sale of its approved medicines and reinvests a significant portion of its earnings into research and development to discover new treatments. Amgen's commitment to innovation and patient care has positioned it as a key player in the biotechnology industry, with a strong pipeline of potential new therapies in various stages of development.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1980
- Headquarters
- Thousand Oaks, United States
- Listing
- IPO 1983
- Employees
- 27,904
- Open positions
- None listed
- Dealroom signal
- 62.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Charity, Biotechnology, Oncology, Inflammatory Diseases, Anti-Fraud, Arts & Culture, EIT KIC Partners, Horizon Europe, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 36 companies, latest Jan 2026
- Capital deployed
- $1.4B
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Feb 2026 | $4B | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2024 | $14M | — | FM | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Amgen is 230K monthly website visits, up 0% over the last three months. Amgen's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Dark Blue TherapeuticsOxford, United KingdomPrecision oncology therapies targeting novel cancer vulnerabilities
$840Mvaluation
Soufflé TherapeuticsWatertown, United StatesTargeted siRNA medicines for genetic and autoimmune diseases
$800Mvaluation
QuantinuumCambridge, United KingdomFull-stack quantum solutions for high-fidelity computation
$13Bvaluation
Generate BiomedicinesSomerville, United StatesPioneering Generative Biology to create breakthrough medicines
$2Bvaluation
Horizon TherapeuticsDublin, IrelandBiopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address critical needs for people affected by rare and rheumatic diseases
$28Bvaluation
Neumora TherapeuticsWatertown, United StatesPioneering a new era of precision medicines for brain diseases
$74Mvaluation
ChemoCentryxSan Carlos, United StatesDevelops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants
$708Mvaluation
TeneobioNewark, United StatesInnovative multi-specific antibodies targeting cancer, autoimmune disorders, and infectious diseases
$900Mvaluation
Rodeo TherapeuticsSeattle, United StatesDevelopment of a new class of small molecule therapies that promotes tissue repair and regeneration
$55Mvaluation
Five Prime TherapeuticsSouth San Francisco, United StatesInnovative Protein Therapeutics
$1.9Bvaluation
SomaLogicBoulder, United StatesUnlocking protein biomarkers to transform healthcare
$460Mvaluation
Carmot TherapeuticsSan Francisco, United StatesDedicated to the discovery and development of innovative medicines
$2.7Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Asset Management Ventures
Series B and later4 investors entered at this stage
Bank of America
Citibank UK
Schrum Private Wealth Management
FM
Other known investors11 additional known investors
5AM Ventures
BOM - Brabant Regional Development Agency
Domain Associates
Earlybird Venture Capital
International Biotechnology Trust
InterWest Partners
Lightstone Ventures
New Leaf Venture Partners
U.S. Venture Partners
US Biomedical Advanced Research and Development Authority
Ysios Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amgen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amgen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.